Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/183972
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Vachiéry, Jean-Luc | - |
dc.contributor.author | Galiè, Nazzareno | - |
dc.contributor.author | Barberà i Mir, Joan Albert | - |
dc.contributor.author | Frost, Adaani E. | - |
dc.contributor.author | Ghofrani, Hossein-Ardeschir | - |
dc.contributor.author | Hoeper, Marius M | - |
dc.contributor.author | McLaughlin, Vallerie V. | - |
dc.contributor.author | Peacock, Andrew J. | - |
dc.contributor.author | Simonneau, Gérald | - |
dc.contributor.author | Blair, Christiana | - |
dc.contributor.author | Miller, Karen L. | - |
dc.contributor.author | Langley, Jonathan | - |
dc.contributor.author | Rubin, Lewis J. | - |
dc.contributor.author | AMBITION Investigators | - |
dc.date.accessioned | 2022-03-09T19:16:49Z | - |
dc.date.available | 2022-03-09T19:16:49Z | - |
dc.date.issued | 2019-02 | - |
dc.identifier.issn | 1053-2498 | - |
dc.identifier.uri | http://hdl.handle.net/2445/183972 | - |
dc.description.abstract | Background: In the randomized, double-blind, event-driven AMBITION study, initial combination therapy with ambrisentan and tadalafil was associated with a 50% reduction in risk of clinical failure (first occurrence of all-cause death, hospitalization for worsening pulmonary arterial hypertension [PAH], disease progression, or unsatisfactory long-term clinical response) vs pooled monotherapy. These results were primarily driven by a reduction in PAH-related hospitalization in the combination therapy group, although a significant effect was not observed in a post-hoc analysis of all-cause hospitalization. Methods: The effect of initial combination therapy with ambrisentan and tadalafil in AMBITION was further explored to study PAH-related hospitalization, which was not reported in the primary publication. Results: Initial combination therapy was associated with a 63% reduction in risk of PAH-related hospitalization when compared with pooled monotherapy (hazard ratio [HR] 0.372, 95% confidence interval [CI] 0.217 to 0.639, p = 0.0002). For every 9 patients treated with combination therapy vs monotherapy, 1 PAH-related hospitalization could be prevented over a 1-year period. Serious adverse events leading to hospitalization, not necessarily PAH-related, occurred in 87 of 253 (34%) and 89 of 247 (36%) of patients on combination therapy and pooled monotherapy, respectively (post-hoc summary). Conclusions: Initial combination therapy with ambrisentan and tadalafil was found to reduce the risk of PAH-related hospitalization by 63% compared with pooled monotherapy. | - |
dc.format.extent | 9 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Elsevier | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1016/j.healun.2018.11.006 | - |
dc.relation.ispartof | Journal of Heart and Lung Transplantation, 2019, vol. 38, num. 2, p. 194-202 | - |
dc.relation.uri | https://doi.org/10.1016/j.healun.2018.11.006 | - |
dc.rights | cc-by-nc-nd (c) Elsevier, 2019 | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | - |
dc.source | Articles publicats en revistes (Medicina) | - |
dc.subject.classification | Hipertensió pulmonar | - |
dc.subject.classification | Vasodilatadors | - |
dc.subject.other | Pulmonary hypertension | - |
dc.subject.other | Vasodilators | - |
dc.title | Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension‒related hospitalization in the AMBITION trial | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 720534 | - |
dc.date.updated | 2022-03-09T19:16:49Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
Appears in Collections: | Articles publicats en revistes (Medicina) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
720534.pdf | 349.06 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License